HIV Infection Clinical Trial
Official title:
Cardiovascular Disease Risk Reduction for Persons With HIV Infection: a Polypill Pilot Study
Verified date | October 2017 |
Source | Minneapolis Medical Research Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is funded by the American Heart Association. The goal of this research is to
prevent early cardiovascular damage before symptoms develop for persons with HIV infection.
Evidence suggests that taking low doses of blood pressure and cholesterol medication reduces
risk for heart disease in persons who are at increased risk (such as the case with HIV
infection).
Participants who are taking HIV treatment with an 'undetectable' viral load, and who do NOT
need treatment for high blood pressure or cholesterol may be eligible to enroll. Participants
will take a low dose cholesterol medication (or placebo) and a low dose of a blood pressure
medication (or a placebo), and will be seen at 3 study visits over 4 months.
Status | Completed |
Enrollment | 37 |
Est. completion date | May 2011 |
Est. primary completion date | December 2010 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years and older |
Eligibility |
Inclusion Criteria: - HIV Infection with viral load 'undetectable' while taking antiretroviral therapy - Age =40 - Framingham risk score (FRS) =5%, or =3% with =5 years of exposure to antiretroviral therapy Exclusion Criteria: - Known cardiovascular disease or Framingham risk score (FRS) =20% - Blood pressure =140/90 - LDL cholesterol =160 (with FRS <10%), or =130 (with FRS 10-20%) - Currently taking, or has a medication contraindication to take, a 'statin', an ACE inhibitor, or an angiotensin receptor blocker medication - Cirrhosis or plasma ALT/AST levels >2x upper limit of normal - Chronic kidney disease and a creatinine >2.0mg/dL - Triglycerides >500mg/dL |
Country | Name | City | State |
---|---|---|---|
United States | Hennepin County Medical Center | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Minneapolis Medical Research Foundation | American Heart Association |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Who Stated (by Self-report) That They Had Side Effects | Participants were asked at each visit if they had any side effects to study medication. They provided a yes or no answer, and if yes they specified what the side effect was. | 4 months | |
Primary | Number of Participants Who Took >90% of Their Doses (by Pill Count) | The number of pills missing from study medication bottles was counted by study nurses at the completion of the study. The proportion of pills taken divided by the number of days the participant was enrolled in the study was calculated, and multiplied by 100, to generate the '% of doses taken' | 4 months | |
Primary | Change From Baseline to Month 4 in the Framingham Risk Score (FRS) | The Framingham Risk Score is calculated by a published algorithm that predicts a patients risk of having a coronary heart disease event in the next 10 years. The measures that are considering in predicting this risk are: age, blood pressure, cholesterol (both total cholesterol and high-density lipoprotein cholesterol), smoking status, and use of medication to treat hypertension. This risk score can be estimated using an online calculator (http://hp2010.nhlbihin.net/atpiii/calculator.asp) | Change from baseline to 4 months | |
Secondary | Changes in Blood Pressure | Blood pressure was assessed by standard clinical methods (i.e., the same way it is measured during a routine clinic visit) | change from baseline to 4 months | |
Secondary | Changes in Blood Lipids | Blood lipids include routine cholesterol measurements that are monitored in clinical practice. They are measured in blood after a blood draw is performed. The specific measurements include: a) total cholesterol, b) low-density lipoprotein cholesterol, c) high-density lipoprotein cholesterol, and d) triglycerides | change from baseline to 4 months | |
Secondary | Changes in Small Artery Elasticity | Small artery elasticity is a measure of vascular function, estimated through analysis of the blood pressure waveform. A sensor is placed on wrist over the radial pulse. The blood pressure waveform of the pulse is recorded and analyzed the elasticity, or compliance, of the small (and large) vasculature. Impaired artery elasticity, or increased stiffness, is an early sign of vascular disease that predicts risk for future cardiovascular events. | change from baseline to 4 months | |
Secondary | Changes hsCRP (C-reactive Protein) | This biomarker represents systemic inflammation within in the body. | change from baseline to 4 months | |
Secondary | Changes IL-6 (Interleukin-6) | This biomarker represents systemic inflammation within in the body. | change from baseline to 4 months | |
Secondary | Changes TNFa (Tumor Necrosis Factor Alpha) | This biomarker represents systemic inflammation within in the body. | change from baseline to 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01702974 -
Immune Reconstitution in HIV Disease (IREHIV)
|
Phase 2 |